Skip to main content
OpenTrials
Completed

NCT Number: NCT01769560

MeFirst: A Tailored Intervention to HPV Vaccine Decision Making

This study will test whether a tailored, online educational intervention increases HPV vaccine uptake and intent among female college students.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Human Papillomavirus-Related Carcinoma

Age range

18 year–26 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Univeristy of Michigan

Ann Arbor, Michigan, 48109, United States

About this study

MeFirst is the first web-based, online, educational tool designed to promote Human Papillomavirus (HPV) vaccine awareness and understanding in an effort to improve HPV vaccine intent and uptake among female university students. HPV is the most common sexually transmitted infection and causes genital warts and cancer. The HPV vaccine has been recommended for girls ages 11-26 since 2006, yet vaccination rates remain low. Tailored online interventions may be more effective tools to promote behavior change among college students than traditional static interventions. The proposed study is a randomized controlled trial testing the efficacy of the MeFirst tool vs. standard static educational material on increasing HPV vaccination intent and uptake among female university students aged 18-26.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • enrolled at the University of Michigan

Exclusion criteria

  • receipt of any doses of HPV vaccine

Treatment and study plan

MeFirst Tailored Intervention

Behavioral

Participants will be lead through MeFirst, an interactive web-based tool that is tailored to their responses during the survey. This tool provides information regarding HPV Vaccination.

Primary outcomes

  1. Determine the effect of the MeFirst tool, a tailored, online HPV vaccination decision-making guide, on HPV vaccination intention and/or uptake.

    Time frame: Immediately post intervention, 3 months and 12 months

    Intention will be assessed on a five-point scale immediately after and at 3 and 12 months. Uptake will be assessed by yes/no/don't know response to the statement, "I have received at least 1 dose of the HPV vaccine" at 3 and 12 months.

Secondary outcomes

  1. Determine the effect of the MeFirst tool on HPV-related knowledge.

    Time frame: Immediately post intervention, 3 months and 12 months

    Comparing 5 or 10-point scales measuring participants' HPV-related knowledge (HPV, HPV vaccination, and cervical cancer) immediately post-intervention and at 3 months and 12 months.

Other outcomes

  1. Determine acceptability of the MeFirst tool to participants.

    Time frame: Immediately post intervention, 3 months and 12 months

    Participants answer five 5-point scale questions about the acceptability of the MeFirst tool immediately post intervention, and at 3 months and 12 months.

Sponsors and collaborators

Lead sponsor

University of Michigan

Other

Registry information

Important dates

Study start
2013
Primary completion
2014
Study completion
2014
First posted
Jan 16, 2013
Registry last updated
Jul 22, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.